The Center for Biosimilars® recaps the top news for the week of November 19, 2018.
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of November 19.
Number 5: Sandoz has launched its infliximab biosimilar, Zessly, in the European Union.
Number 4: During the Annual Scientific Meeting of the American College of Gastroenterology, researchers from the United Kingdom reported on yet another large, nonmedical switch from reference infliximab to biosimilar CT-P13.
Number 3: Denmark’s national authorities have confirmed to The Center for Biosimilars® that Humira did not offer the lowest price for its adalimumab biosimilar in either of 2 national tenders.
Number 2: Pfizer has announced that it has launched its epoetin alfa biosimilar, Retacrit, at a 33.5 percent discount to the reference product, Epogen.
Number 1: Samsung BioLogics, parent company of the biosimilar development business Samsung Bioepis, has been fined by the Republic of Korea’s financial regulatory body after the commission ruled that Samsung had committed fraud.
Finally, last week, our e-newsletter asked if Democrats and Republicans are likely to find common ground in regard to lowering drug prices.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.